Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H6O4.C5H12N2.Pt |
| Molecular Weight | 437.356 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Pt++].NC[C@H]1CCCN1.[O-]C(=O)C2(CCC2)C([O-])=O
InChI
InChIKey=XXUHLUDUCZQMDI-UTYJZAQGSA-L
InChI=1S/C6H8O4.C5H12N2.Pt/c7-4(8)6(5(9)10)2-1-3-6;6-4-5-2-1-3-7-5;/h1-3H2,(H,7,8)(H,9,10);5,7H,1-4,6H2;/q;;+2/p-2/t;5-;/m.1./s1
| Molecular Formula | C6H6O4 |
| Molecular Weight | 142.1094 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C5H12N2 |
| Molecular Weight | 100.1622 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Pt |
| Molecular Weight | 195.084 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Miboplatin (DWA 2114R) is a platinum analog developed for the treatment of cancer. Miboplatin is an alkylating agent that reached phase III clinical trials in Japan. In spite of its good anticancer activity, the drug did not show any advantage over cisplatin. Further development of this drug for the treatment of breast, ovarian and prostate cancer was discontinued.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:32:40 GMT 2025
by
admin
on
Mon Mar 31 19:32:40 GMT 2025
|
| Record UNII |
06241B5S4P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6848
Created by
admin on Mon Mar 31 19:32:40 GMT 2025 , Edited by admin on Mon Mar 31 19:32:40 GMT 2025
|
PRIMARY | |||
|
C175820
Created by
admin on Mon Mar 31 19:32:40 GMT 2025 , Edited by admin on Mon Mar 31 19:32:40 GMT 2025
|
PRIMARY | |||
|
DTXSID70908584
Created by
admin on Mon Mar 31 19:32:40 GMT 2025 , Edited by admin on Mon Mar 31 19:32:40 GMT 2025
|
PRIMARY | |||
|
103775-75-3
Created by
admin on Mon Mar 31 19:32:40 GMT 2025 , Edited by admin on Mon Mar 31 19:32:40 GMT 2025
|
PRIMARY | |||
|
06241B5S4P
Created by
admin on Mon Mar 31 19:32:40 GMT 2025 , Edited by admin on Mon Mar 31 19:32:40 GMT 2025
|
PRIMARY | |||
|
SUB08942MIG
Created by
admin on Mon Mar 31 19:32:40 GMT 2025 , Edited by admin on Mon Mar 31 19:32:40 GMT 2025
|
PRIMARY | |||
|
72031
Created by
admin on Mon Mar 31 19:32:40 GMT 2025 , Edited by admin on Mon Mar 31 19:32:40 GMT 2025
|
PRIMARY | |||
|
100000081165
Created by
admin on Mon Mar 31 19:32:40 GMT 2025 , Edited by admin on Mon Mar 31 19:32:40 GMT 2025
|
PRIMARY | |||
|
m830
Created by
admin on Mon Mar 31 19:32:40 GMT 2025 , Edited by admin on Mon Mar 31 19:32:40 GMT 2025
|
PRIMARY | Merck Index | ||
|
36143
Created by
admin on Mon Mar 31 19:32:40 GMT 2025 , Edited by admin on Mon Mar 31 19:32:40 GMT 2025
|
PRIMARY |